ライフサイエンスコーパス: creatinine clearance

1 er moderate to severe AKI (>50% reduction in creatinine clearance).

2 files, and 24-hour urine for proteinuria and creatinine clearance.

3 < 0.0001) levels, as well as improvement of creatinine clearance.

4 itial diuresis, but no significant change in creatinine clearance.

5 biopsy-proven acute rejection and estimated creatinine clearance.

6 creatinine, BUN, folate concentrations, and creatinine clearance.

7 in less pronounced albuminuria and increased creatinine clearance.

8 ea plasma levels and less severe decrease in creatinine clearance.

9 (1350-1800 mg/12 hr) corrected according to creatinine clearance.

10 rmalized renal blood flow, but did not alter creatinine clearance.

11 uch as elevated blood pressure and decreased creatinine clearance.

12 ing two boluses had no beneficial effects on creatinine clearance.

13 d creatinine clearance, and endogenous 24-hr creatinine clearance.

14 35 mL/minute (95% CI = 3.98-16.77) in GFR or creatinine clearance.

15 type, BMI, average drug dose, adherence, and creatinine clearance.

16 rine output of 40 to 260 mL/h and increasing creatinine clearance.

17 colistimethate and colistin were related to creatinine clearance.

18 ard and kinetic equations as well as urinary creatinine clearance.

19 d be needed to achieve a desired Css,avg and creatinine clearance.

20 HS diet did not affect creatinine clearance.

21 t of apolipoprotein A-I, HDL cholesterol, or creatinine clearance.

22 m of age, body weight, creatinine level, and creatinine clearance.

23 data from 214 adult critically-ill patients (creatinine clearance 0-236mL/min; 29 receiving renal rep

24 data from 214 adult critically-ill patients (creatinine clearance 0-236mL/min; 29 receiving renal rep

25 Mean estimated creatinine clearance 1 year posttransplant was 93.2+/-33

26 udy period compared with the mean calculated creatinine clearance (119.5 +/- 57.2 vs 77.8 +/- 27.6 mL

27 %), heart rate (-14%), blood pressure (-7%), creatinine clearance (-12%), energy cost of walking (-22

28 % +/- 90%), urinary PO2 (+164% +/- 80%), and creatinine clearance (+120% +/- 65%) at 30 minutes.

29 -12 mL/min/1.73 m; Cockcroft-Gault estimated creatinine clearance, 125+/-33 and 85+/-22 mL/min/1.73 m

30 tion (467+/-74 versus 174+/-23 mug/d), lower creatinine clearance (126+/-29 versus 452+/-63 mul/min),

31 85+/-22 mL/min/1.73 m, and endogenous 24-hr creatinine clearance, 133+/-38 and 86+/-24 mL/min/1.73 m

32 ced to 30 mg per day if one or more factors (creatinine clearance 15-50 mL/min, low bodyweight [</=60

33 urine volume (299 vs. 80 mL, p < 0.001) and creatinine clearance (161.4 vs. 123.4 mL/min, p = 0.03)

34 model, elevated circulating ouabain reduced creatinine clearance (-18%, p < 0.05), increased urinary

35 serum creatinine 6 months and the estimated creatinine clearance 2 years after transplantation.

36 were subjected to 5/6 subtotal nephrectomy (creatinine clearance, 25% normal).

37 mg/L and >/=4 mg/L extended to patients with creatinine clearance 30 to <50 mL/min.

38 ically suppressed HIV-infected adults with a creatinine clearance 30 to <50 mL/minute receiving TDF 3

39 misation or during the trial if patients had creatinine clearance 30-50 mL/min, bodyweight 60 kg or l

40 , 1.23-, 1.61-, and 1.47-fold enhancement of creatinine clearance, 3000-Da dextran clearance, 70 000-

41 Subjects with preexisting renal impairment (creatinine clearance, 40-60 mL/minute) received 75 mg os

42 years), weight 51 kg (range, 38-80 kg), and creatinine clearance 43.9 mL/minute (range, 30.9-49.7 mL

43 9.7 (12.2) years, weight 74.5 (20.3) kg, and creatinine clearance 56.8 (38.2) mL/minute were enrolled

44 +/- 0.7 mg/dL), or Cockroft Gault calculated creatinine clearance (58.6 +/- 19.7; 59.8 +/- 20.5 mL/mi

45 lative Illness Rating Scale score, 8; median creatinine clearance, 66.4 ml per minute) underwent rand

46 m creatinine (0.97-0.99 mg/dL), and baseline creatinine clearance (85.0-85.4 mL/minute).

47 years; 95% CI: 1.6 to 4.8); and had a lower creatinine clearance (-9.9 ml/min; 95% CI: -11.3 to -8.4

48 Data to estimate creatinine clearance according to the Cockcroft-Gault an

49 e from 10,236 patients, and data to estimate creatinine clearance according to the six- and four-vari

50 eservation by HMPox100% led to a doubling of creatinine clearance after 90 and 120 min of reperfusion

51 ria, increased serum creatinine, and reduced creatinine clearance (AKI), but there were no changes ov

52 ncology Group performance status, WBC count, creatinine clearance, albumin, AST, number of study drug

53 The renal allograft function by calculated creatinine clearance also significantly improved at 40.6

54 arkers (haematocrit, cTnI-hs, cystatin C, or creatinine clearance) also outperformed the HAS-BLED and

55 kidney injury, as reflected by the measured creatinine clearance, alters both pharmacokinetics and p

56 The diabetic 10% hypomorphs had comparable creatinine clearance and albumin excretion to wild-type

57 evated plasma creatinine and urea, decreased creatinine clearance and albuminuria) were progressively

58 sed a transient rise in plasma Pi levels and creatinine clearance and an increase in phosphaturia wit

59 angiotensin II type 1 receptor reduced renal creatinine clearance and apical ENaC localization, and c

60 ant decreases in cross-sectional measures of creatinine clearance and GFR in the tenofovir group comp

61 Creatinine clearance and glomerular filtration rate (GFR

62 Patient creatinine clearance and graft status was followed up po

63 00 mg daily, which was adjusted according to creatinine clearance and hemoglobin values.

64 heep, infusion of Escherichia coli decreased creatinine clearance and increased plasma creatinine, re

65 leeding, mild anemia, and a lower calculated creatinine clearance and less likely to be female or hav

66 parathyroidectomized rats also led to higher creatinine clearance and lower plasma calcium levels but

67 Doripenem clearance was correlated with creatinine clearance and peripheral volume of distributi

68 Ambrisentan improved creatinine clearance and podocyte effacement in eNOS-def

69 gatran before the procedure was based on the creatinine clearance and procedure-related bleeding risk

70 led to statistically significant declines in creatinine clearance and serious renal adverse events (d

71 ntravenous zoledronic acid 4 mg adjusted for creatinine clearance and subcutaneous placebo (n = 1,020

72 c association between percentage decrease in creatinine clearance and the number of doses of tenofovi

73 Changes in potassium excretion, creatinine clearance, and body weight also were evaluate

74 The total urine volume, creatinine clearance, and change in plasma renin activit

75 imated GFR (eGFR), Cockcroft-Gault estimated creatinine clearance, and endogenous 24-hr creatinine cl

76 cure, bacteriological clearance, daily serum creatinine clearance, and estimated creatinine clearance

77 reased renal blood flow, oliguria, decreased creatinine clearance, and increased serum creatinine.

78 Donor age, body mass index, creatinine clearance, and ischemic time were independent

79 ance, changes in CD4 cell counts, calculated creatinine clearance, and lipid levels.

80 ST-segment elevation myocardial infarction, creatinine clearance, and troponin ratio were all indepe

81 indings (low baseline hemoglobin and reduced creatinine clearance), antiplatelet agent-related factor

82 Surprisingly, renal creatinine clearance as estimated from mass, age, and pl

83 The mean creatinine clearance at 1 and 3 years is 58 mL/min and 6

84 clearance compared with the mean calculated creatinine clearance based on the Cockcroft-Gault equati

85 Patients with creatinine clearance below 30 were excluded.

86 not affect the time course of creatinine and creatinine clearance but did increase plasma urea, urea/

87 to high in the podocytes markedly decreased creatinine clearance, but minimally increased albumin ex

88 ths, and 8 patients matched by age, sex, and creatinine clearance, but with intact parathyroid hormon

89 of the serum creatinine level, reduction in creatinine clearance by 50% or more, progression to end-

90 talization: age, Charlson comorbidity score, creatinine clearance, calcium level, below-normal white

91 P group demonstrated significantly increased creatinine clearance calculated on POD3 (63.6 +/- 19.0 m

92 >/=2, and >/=4 mg/L were determined for each creatinine clearance category (>/=80 mL/min, 50 to <80 m

93 evaluate the association between calculated creatinine clearance (CCC)-based contrast dose and renal

94 imated kidney function using Cockcroft-Gault creatinine clearance (CCl), Modification of Diet in Rena

95 Unique calculated variables included creatinine clearance (cCrCl) and Pediatric End-Stage Liv

96 Calculated creatinine clearance (Cockcroft and Gault formula) at 1

97 Estimated creatinine clearance (Cockcroft-Gault) from baseline out

98 chnoid hemorrhage had a higher mean measured creatinine clearance compared with the mean calculated c

99 1.73 m; p < 0.0001) and higher mean measured creatinine clearance compared with the mean calculated e

100 1.73 m; p < 0.0001) and higher mean measured creatinine clearance compared with the mean calculated e

101 Estimated renal creatinine clearance correlated with the extent of activ

102 The clinical biomarkers, namely: creatinine clearance (CrCl) and serum plasma creatinine

103 iruses BKV and JCV and their relationship to creatinine clearance (CrCl) in a longitudinal study of 4

104 9 mg kg(-1)) did not change MAP, HR, RBF, or creatinine clearance (CrCl) in SD rats (n = 7).

105 versus warfarin across the range of baseline creatinine clearance (CrCl) in the ENGAGE AF-TIMI 48 tri

106 Creatinine clearance (CrCl) overestimated I-iothalamate

107 Pretreatment renal function was defined as creatinine clearance (CrCl) using the Cockcroft-Gault eq

108 ese values were used to assign a category of creatinine clearance (CrCl) using the Cockcroft-Gault fo

109 At 7 days in 2K, serum creatinine clearance (CrCl) was decreased only in CsA/SR

110 were measured at study week 2, and rates of creatinine clearance (CrCl) were estimated using the Coc

111 statin C equation to that of 24-hour urinary creatinine clearance (CrCl), Cockcroft-Gault (CG), and p

112 The performance of creatinine clearance (CrCl), Modification of Diet in Ren

113 d on the creatinine level and the calculated creatinine clearance (CrCl).

114 stroke, and new requirement for dialysis by creatinine clearance (CrCl).

115 t-to-treat population included 929 patients (creatinine clearance [CrCL] >=15 to <50 mL/min, n = 85 a

116 ndomly assigned 134 adult patients with CKD (creatinine clearance [CrCl] 15 to 30 ml/min per 1.73 m(2

117 advanced chronic kidney disease (defined as creatinine clearance [CrCl] 25 to 30 mL/min) enrolled in

118 Creatinine clearance decreased similarly in both groups.

119 r transient ischemic attack, diabetes, lower creatinine clearance, decreased hematocrit, aspirin ther

120 lic blood pressure were largely similar, and creatinine clearance did not differ between groups.

121 ration, renal sodium and chloride excretion, creatinine clearance, diuretic therapy, pH, known diabet

122 of renal function and routine monitoring of creatinine clearance during follow-up, tenofovir can be

123 The estimated creatinine clearance during sustained low-efficiency dia

124 with hemoglobin <11.5 g/dl and an estimated creatinine clearance (eCrCl) <50 ml/min per 1.73 m(2).

125 tio, spot urine albumin to creatinine ratio, creatinine clearance, estimated glomerular filtration ra

126 +/-0.29 mg/dL; corresponding mean calculated creatinine clearance estimates were 70+/-18, 73+/-17, an

127 Creatinine clearance fell from 109.8 +/- 22.3 mL/min per

128 reatinine, serum aspartate aminotransferase, creatinine clearance, fractional excretion of Na(+), and

129 erular filtration rate estimation by urinary creatinine clearance frequently fails to detect renal im

130 Reductions in creatinine clearance from baseline were calculated and p

131 e use of statin, we found that the change in creatinine clearance from preoperative to postoperative

132 serum cystatin C and the reduced inulin and creatinine clearance from the circulation, suggested tha

133 ith a stratified dose reduction for impaired creatinine clearance, given as a CMV prophylaxis for 3 t

134 ed renal clearance was defined by a measured creatinine clearance greater than or equal to 130 mL/min

135 ed renal clearance was defined as a measured creatinine clearance greater than the calculated creatin

136 can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in co

137 can be safely administered to patients with creatinine clearance > 30 mL/min (grade A).

138 ent RD was defined as a relative decrease of creatinine clearance >/= 25% over baseline at 3 months.

139 on), 14 264 patients with nonvalvular AF and creatinine clearance >/=30 mL/min were randomized to riv

140 For patients with creatinine clearance >/=80 mL/min, only approximately 65

141 eved Css,avg >/=2mg/L; but for patients with creatinine clearance >/=80mL/min target attainment was <

142 eved Css,avg >/=2mg/L; but for patients with creatinine clearance >/=80mL/min target attainment was <

143 individuals with cardiovascular disease and creatinine clearance >30 ml/min) and examined post hoc t

144 Medically ill patients with a baseline creatinine clearance >=50 ml/min were randomized in a do

145 polycystic kidney disease (ADPKD; estimated creatinine clearance, >/=60 ml per minute), the vasopres

146 The PRECISE-DAPT score (age, creatinine clearance, haemoglobin, white-blood-cell coun

147 eep with nonhypotensive hyperdynamic sepsis, creatinine clearance halved (32 to 16 mL/min, ratio [95%

148 rebrovascular accident, smoking history, and creatinine clearance (hemoglobin level showed a strong t

149 ogen, sICAM-1, homocysteine, lipoprotein(a), creatinine clearance, high-density lipoprotein cholester

150 r body mass index (BMI), male sex, increased creatinine clearance, higher lipoprotein(a) level, prote

151 ared with the UW group (area under the curve creatinine clearance; HMP 9.8+/-7.3, HOC 2.2+/-1.7, UW 1

152 Six-hour creatinine clearance, hourly plasma/urinary furosemide c

153 ST deviation (HR, 1.39; 95% CI, 1.19-1.63), creatinine clearance (HR, 0.88; 95% CI, 0.83-0.94), Kill

154 infarction, femoral access for angiography, creatinine clearance, hypercholesterolemia, and arterial

155 eventually progressed to CKD, with decreased creatinine clearance, hyperphosphatemia, and renal fibro

156 1 month and 1 year posttransplant, estimated creatinine clearance improved from 59+/-13 mL/min at 1 m

157 rrelation between renal blood flow index and creatinine clearance in patients with septic acute kidne

158 atients were on continuous hemodialysis, and creatinine clearance in the other patients was 10-143 mL

159 predicted (p = 0.019) sustained elevation of creatinine clearance in these patients over the first we

160 Endogenous creatinine clearance is the most common method used to m

161 Creatinine clearance is usually increased by statins.

162 Creatinine clearance, kidney graft size, and glomerular

163 epatitis B virus surface antigen, pregnancy, creatinine clearance less than 60 mL per min, treatment

164 Cisplatin ineligibility was defined as creatinine clearance less than 60 mL/min (but >= 30 mL/m

165 0 mg/day (P75) at 1-year postconversion were creatinine clearance less than 60 mL/min (odds ratio [OR

166 tive Oncology Group performance status of 2, creatinine clearance less than 60 mL/min, grade >/= 2 he

167 Karnofsky performance status of 60% to 70%, creatinine clearance less than 60 mL/min, visceral metas

168 In multivariate models, age and baseline creatinine clearance less than 90 mL/min predicted decli

169 level, folate, serum albumin and creatinine, creatinine clearance, lipid status, body mass index (BMI

170 The progressive kidney (creatinine levels, creatinine clearance), liver (transaminase activities, b

171 ents with severe renal impairment (SRI, i.e. creatinine clearance < 30ml/min).

172 groups (age >/= 75 years, stage III myeloma, creatinine clearance < 60 mL/min).

173 ney for elimination, such that patients with creatinine clearance <25 ml/min were excluded from all t

174 c obstructive pulmonary disease, anemia, and creatinine clearance <30 ml/min were independent predict

175 tients with advanced chronic kidney disease (creatinine clearance <30 ml/min) and those on dialysis.

176 For creatinine clearance <30 mL/min, 100% of patients receiv

177 venting stroke specifically in patients with creatinine clearance <30 ml/min.

178 0-3.0) or rivaroxaban (20 mg daily; 15 mg if creatinine clearance <50 mL/min), double blind.

179 inine increase of >/=0.5 mg/dL [>44 umol/L], creatinine clearance <50 mL/min, or level of PO4 <2 mg/d

180 The inclusion of creatinine clearance <60 mL/min and prior stroke or tran

181 Among 2179 patients with CKD (creatinine clearance <60 mL/min), baseline troponin elev

182 nic Health Evaluation II scores >15, 23% had creatinine clearance <60 mL/min, and 35% were aged >=65

183 s were independently predicted by older age, creatinine clearance <60 mL/min, treatment with coronary

184 Chronic kidney disease was defined as creatinine clearance <60 mL/min.

185 n a non-dialysis day), >80% of patients with creatinine clearance <80mL/min achieved Css,avg >/=2mg/L

186 n a non-dialysis day), >80% of patients with creatinine clearance <80mL/min achieved Css,avg >/=2mg/L

187 Creatinine clearance measured when study drug was stoppe

188 tment WRF (a decrease of >20% from screening creatinine clearance measurement at any time point durin

189 nto the study, contributing 1,660 individual creatinine clearance measures.

190 did so on more than or equal to 50% of their creatinine clearance measures.

191 fovir alafenamide had a smaller reduction in creatinine clearance (median change in estimated glomeru

192 Augmented renal clearance was defined by a creatinine clearance more than or equal to 130 mL/min/1.

193 djusted for traditional CVD risk factors and creatinine clearance, NGAL was a significant predictor o

194 igher TNFalpha was associated with decreased creatinine clearance, nonsmoking status, anemia, and gre

195 mpared according to baseline renal function (creatinine clearance: normal >=80, mild 50 to <80, moder

196 r institution; 1490 of 3986 had an estimated creatinine clearance of <60 mL/min and were enrolled.

197 ency preoperatively (defined as an estimated creatinine clearance of <60 mL/min determined by the Coc

198 dipstick analysis (7 [7%] of 1012 subjects); creatinine clearance of <90 mL/min (195 [18%] of 1071 su

199 n weight of 10.7 (2.9-21.5) kg, and a median creatinine clearance of 179 (44-384) mL/min/1.73m2, who

200 ry diffusion capacity of less than 80%, or a creatinine clearance of 30 mL/min or more but less than

201 ce daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body

202 icating worse health status) or an estimated creatinine clearance of 30 to 69 ml per minute to receiv

203 that enrolled patients with CKD (defined as creatinine clearance of 30-50 ml/min) and reported data

204 y (or 30 mg once per day for patients with a creatinine clearance of 30-50 mL/min, bodyweight <60 kg,

205 clinical response in patients with baseline creatinine clearance of 30-50 mL/min, potentially due to

206 than 18 years and younger than 65 years with creatinine clearance of 30-69 mL/min (calculated by use

207 ative illness rating scale greater than 6, a creatinine clearance of 30-69 mL/min, or both.

208 notable for a hemoglobin of 10.8 g/dL and a creatinine clearance of 36 mL/min.

209 aive HIV-infected patients with an estimated creatinine clearance of 50 mL per min or higher from 178

210 ey volume of 750 ml or more and an estimated creatinine clearance of 60 ml per minute or more, in a 2

211 raft function persists with a current median creatinine clearance of 60 mL/min.

212 The patients had a median age of 73 years, creatinine clearance of 62 ml per minute, and CIRS score

213 t-naive HIV-infected women with an estimated creatinine clearance of 70 mL/min or higher from 80 cent

214 sistance to emtricitabine and tenofovir, and creatinine clearance of 70 mL/min or higher.

215 NA concentrations of at least 5 log10 IU/mL, creatinine clearance of at least 1.0 mL/s, and a platele

216 5 times the upper limit of normal or less, a creatinine clearance of at least 30 mL/min, and a Karnof

217 at least 5 g per 24 hours, and a quantified creatinine clearance of at least 40 ml per minute per 1.

218 ow reserve, adequate hepatic function, and a creatinine clearance of at least 50 mL per min.

219 mes the upper limit of normal, and estimated creatinine clearance of at least 50 mL/min (by the Cockc

220 r at least 6 months before enrolment and had creatinine clearance of at least 50 mL/min.

221 r at least 6 months before enrolment and had creatinine clearance of at least 50 mL/min.

222 scular disease or multiple risk factors, and creatinine clearance of at least 60 mL/min were randomly

223 d function of organ systems) or a calculated creatinine clearance of less than 70 ml per minute were

224 In patients with a calculated serum creatinine clearance of more than 60 mg/min, no change i

225 o receipt of ART in the previous 6 months, a creatinine clearance of more than 60 ml per minute (>80

226 , normal blood cell counts, and a calculated creatinine clearance of more than 60 mL per minute.

227 prehensive metabolic panel with a calculated creatinine clearance of more than 60 mL per minute.

228 al exposure in the previous 6 months, with a creatinine clearance of more than 60 mL/min (>80 mL per

229 c 300% hypermorphs had approximately 1/3 the creatinine clearance of wild-type mice, >20x their album

230 e GNC (n = 4) and all had estimated baseline creatinine clearances of <30ml/min.

231 0.5 vs SCS 2.7 +/- 0.7 mg/dL; P = 0.11) and creatinine clearance on day 10 (NEVKP, 65.9 +/- 18.8 mL/

232 The creatinine clearance on day 4 was increased in NEVKP-pre

233 emphasizes the effect of patient weight and creatinine clearance on pharmacokinetics.

234 ow-up sessions every 12 weeks, participants' creatinine clearance on PrEP was estimated and in a subs

235 of iohexol clearance toward 24-hour urinary creatinine clearance over the same period was -18.1 mL/m

236 hemorrhage, there was a higher mean measured creatinine clearance over the study period compared with

237 (p < 0.01), sodium excretion (p < 0.01), and creatinine clearance (p < 0.001).

238 ion modeling suggested that age (P = 0.001), creatinine clearance (P = 0.01), and height z score (P =

239 d cystatin C (P<0.001), and higher estimated creatinine clearance (P=0.017).

240 BMI (P<0.001) and creatinine clearance (P=0.031) remained associated with

241 ght, plasma blood urea nitrogen, creatinine, creatinine clearance, phosphorus, calcium, parathyroid h

242 , and the combination of MCP-1, AAG, TF, and creatinine clearance plus C4 was a good diagnostic test

243 NGAL together with creatinine clearance plus MCP-1 was an excellent diagnos

244 r ejection fraction (r = -0.134; p = 0.014), creatinine clearance (r = -0.224; p < 0.001), B-type nat

245 P < 0.001), heart rate (r = 0.60, P < 0.05), creatinine clearance (r = 0.79, P < 0.05), negative flui

246 clearance did not show any relationship with creatinine clearance (r(2) = 0.008), APACHE II score, or

247 A model that included creatinine clearance (R(2)CHADS(2)) improved net reclass

248 data from 162 adult critically ill patients (creatinine clearance range, 5.4-211 mL/min) were used to

249 , 1.009; 95% CI, 1.002-1.017; P = .01) and a creatinine clearance rate >/=53 mL/min (OR, 1.024; 95% C

250 Only baseline creatinine clearance rate >/=53 mL/min predicted 6-week

251 ared kidneys, we also quantified the average creatinine clearance rate per glomerulus.

252 d prechemotherapy values, platelet count and creatinine clearance rate, predict IA outcome and strati

253 iphered creatinine excretion then yields the creatinine clearance rate.

254 ncentrations with reduced urinary calcium to creatinine clearance ratios (CCCR) in comparison with FH

255 heir albumin excretion more than 10-fold but creatinine clearance remained high.

256 The 24-hour creatinine clearance remains the mainstay for kidney fun

257 Patients whose creatinine clearance returned to baseline (or nearly) we

258 Clinic and ambulatory BP, creatinine clearance, sodium and protein intake, and gly

259 fter transplant was associated with improved creatinine clearance, suggesting continued adaptation ov

260 Twenty-four hours after a 90% reduction in creatinine clearance, the rise in SCr was 246% with norm

261 ose, glycosylated hemoglobin, creatinine, or creatinine clearance; therefore, PAI-1R may prevent prog

262 s patient group, with sustained elevation of creatinine clearance throughout the first week in ICU.

263 ood pressure, sympathetic nerve activity and creatinine clearance to diabetic Cav2.2(+/+) mice.

264 imal serum creatinine levels and recovery of creatinine clearance to normal values compared with CS.

265 for this purpose [GFR measurement by urinary Creatinine Clearance (uCrCl) versus GFR estimation (eGFR

266 Estimated GFR and 24-hr plasma creatinine clearance underestimate GFR with greater vari

267 Urinary creatinine clearance underestimated renal impairment in

268 enal function criteria should enable liberal creatinine clearance, unless the investigational agent i

269 nt-related concern, then patients with lower creatinine clearance values of > 30 mL/min should be inc

270 tinine clearance greater than the calculated creatinine clearance via Cockcroft-Gault and estimated g

271 The slope of calculated creatinine clearance was -0.66 mL/min/month over 6 month

272 ng a median of 72 weeks, the mean decline in creatinine clearance was -2.9% (95% CI -2.4 to -3.4; ptr

273 Median change in estimated creatinine clearance was 1.2 mL/min in the tacrolimus gr

274 Baseline creatinine clearance was 52.4+/-17.8 mL/min vs. 53.4+/-2

275 Calculated creatinine clearance was 66+/-26 mL/min at 2 years.

276 as 67.8 years, 55.5% were men, mean baseline creatinine clearance was 87.8 ml/min, and mean duration

277 Reduced creatinine clearance was a strong, independent predictor

278 Creatinine clearance was also calculated using the Cockc

279 Creatinine clearance was also similar between groups (in

280 In pooled analysis, baseline creatinine clearance was associated with observed TFV-DP

281 The creatinine clearance was calculated for estimation of th

282 t EOP, liver function tests were similar but creatinine clearance was higher in micafungin- vs standa

283 The creatinine clearance was inversely associated with preop

284 Creatinine clearance was preserved in the Dox + Erl rats

285 nse to furosemide also became important when creatinine clearance was reduced to less than 40 mL/min/

286 -2.2, HTK 5.6+/-1.9 mm Hg/min; P=0.006), and creatinine clearance was significantly higher compared w

287 Mean calculated creatinine clearance was significantly lower in group B

288 Renal function assessed by creatinine clearance was similar for both groups.

289 Measured creatinine clearance was strongly associated with the am

290 Adjusted creatinine clearance was unchanged over the 10 days.

291 Proteinuria, but not creatinine clearance, was associated with higher percent

292 enal function, as measured by an increase in creatinine clearance, was maintained and the rate of inc

293 Among BOC recipients, lower baseline Hb and creatinine clearance were associated with incident anemi

294 Eight-hour urine collections to measure creatinine clearance were collected daily as the primary

295 of high grade proteinuria, urine sodium and creatinine clearance were measured.

296 ly serum creatinine clearance, and estimated creatinine clearance were recorded.

297 Eight-hour urinary creatinine clearances were collected daily, as the prima

298 fection, but in patients with BKV infection, creatinine clearances were lower at times when viral she

299 potassium, lithium, para-aminohippurate, and creatinine clearances were measured before, during, and

300 ot change renal blood flow, urine output, or creatinine clearance, whereas infusion of Nomega-nitro-L